AdipoGen Life Sciences

anti-LYVE-1 (human), pAb

CHF 320.00
In stock
AG-25T-0100-C100100 µgCHF 320.00
More Information
Product Details
Synonyms Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1; CRSBP-1
Product Type Polyclonal Antibody
Properties
Source/Host Rabbit
Immunogen/Antigen Recombinant human LYVE-1 (aa24-232).
Application

Flow Cytometry: (3-10μg/ml)
Immunohistochemistry: (frozen sections 6-30μg/ml, 1:200)
Western Blot: (1-2μg/ml)
Optimal conditions must be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes human LYVE-1.

Purity Protein A purified.
Purity Detail Protein A purified.
Formulation Lyophilized.
Reconstitution Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0mg/ml.
Isotype Negative Control

Rabbit IgG

Other Product Data

UniProt ID Q9Y5Y7: Lyve-1 (human)

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 6 months after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

Product References
  1. Lymphatic capillary hypoplasia in the skin of fetuses with increased nuchal translucency and Turner's syndrome: comparison with trisomies and controls: C.S. von Kaisenberg, et al.; Mol. Hum. Reprod. 16, 778 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.